Novartis Ag

Hye-Yeon Park

James Neef

Zaixing Li

Tejaskumar Pankajbhai Pathak

Xilin Zhou

Amir Masoud Sadaghiani

Chui Lu

Danuta Lubicka

Sung David C Kim

Thomas Charles Caya

The present disclosure provides for a compound according to formula (I)

Methyl (R)-2-(fluoromethyl)-5-oxo-4-phenyl-4,5,6,7-tetrahydro-1H-cyclopenta[B]pyridine-3-carboxylate and methyl 2-(fluoromethyl)-5-oxo-4-phenyl-1,4,5,7-tetrahydrofuro[3,4-b]pyrodine-3-carboxylate as Ca1.2 activators

The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as Ca1.22 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, or early repolarization syndrome.

Methyl (r)-2-(fluoromethyl)-5-oxo-4-phenyl-4,5,6,7-tetrahydro-1H-cyclopenta[b]pyridine-3-carboxylate and methyl (r)-2-(fluoromethyl)-5-oxo-4-phenyl-1,4,5,7-tetrahydrofuro[3,4-b]pyridine-3-carboxylate as CAV1.2 activators

Growing community of inventors

Arlington, MA, United States of America

Hye-Yeon Park